Quốc gia: Vương quốc Anh
Ngôn ngữ: Tiếng Anh
Nguồn: MHRA (Medicines & Healthcare Products Regulatory Agency)
Fentanyl
Teva UK Ltd
N02AB03
Fentanyl
75microgram/1hour
Transdermal patch
Transdermal
Schedule 2 (CD)
Valid as a prescribable product
BNF: 04070200; GTIN: 5702589302845
PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER _Matrifen 12 micrograms/hour transdermal patch _ _Matrifen 25 micrograms/hour transdermal patch _ _Matrifen 50 micrograms/hour transdermal patch _ _Matrifen 75 micrograms/hour transdermal patch _ _Matrifen 100 micrograms/hour transdermal patch _ _ _ _Fentanyl _ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you (or your child) only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Matrifen is and what it is used for 2. What you need to know before you use Matrifen 3. How to use Matrifen 4. Possible side effects 5. How to store Matrifen 6. Contents of the pack and other information 1. WHAT MATRIFEN IS AND WHAT IT IS USED FOR The name of your medicine is Matrifen. The patches help relieve pain that is very bad and long-lasting: • in adults who need continuous pain treatment • in children above 2 years of age who are already using opioid medication and who need continuous pain treatment. Matrifen contains a medicine called fentanyl. It belongs to a group of strong painkillers called opioids. IMPORTANT THINGS YOU NEED TO KNOW ABOUT MATRIFEN TRANSDERMAL PATCHES: These patches contain a strong pain killer Ensure that old patches are removed before applying a new one Patches must not be cut Do not expose the patches to a heat source (such as a hot water bottle) Do not soak in a hot bath or take a hot shower whilst wearing a patch If you develop a fever tell your doctor immediately Follow the dosage instructions carefully and only change your patch at the SA Đọc toàn bộ tài liệu
OBJECT 1 MATRIFEN Summary of Product Characteristics Updated 06-Jul-2017 | Takeda UK Ltd 1. Name of the medicinal product Matrifen, 12 micrograms/hour Transdermal patch Matrifen, 25 micrograms/hour Transdermal patch Matrifen, 50 micrograms/hour Transdermal patch Matrifen, 75 micrograms/hour Transdermal patch Matrifen, 100 micrograms/hour Transdermal patch 2. Qualitative and quantitative composition Matrifen 12 micrograms/hour: Each transdermal patch contains 1.38 mg fentanyl in a patch of 4.2 cm 2 and releases fentanyl 12 micrograms/hour Matrifen 25 micrograms/hour: Each transdermal patch contains 2.75 mg fentanyl in a patch of 8.4 cm 2 and releases fentanyl 25 micrograms/hour Matrifen 50 micrograms/hour: Each transdermal patch contains 5.50 mg fentanyl in a patch of 16.8 cm 2 and releases fentanyl 50 micrograms/hour Matrifen 75 micrograms/hour: Each transdermal patch contains 8.25 mg fentanyl in a patch of 25.2 cm 2 and releases fentanyl 75 micrograms/hour Matrifen 100 micrograms/hour: Each transdermal patch contains 11.0 mg fentanyl in a patch of 33.6 cm 2 and releases fentanyl 100 micrograms/hour For the full list of excipients, see section 6.1. 3. Pharmaceutical form Transdermal patch. Rectangular, translucent patch on a removable protective film. The protective film is larger than the patch. Patches are marked with a coloured imprint stating the trade name and strength: Matrifen 12 micrograms/hour patch: brown imprint Matrifen 25 micrograms/hour patch: red imprint Matrifen 50 micrograms/hour patch: green imprint Matrifen 75 micrograms/hour patch: light blue imprint Matrifen 100 micrograms/hour patch: grey imprint 4. Clinical particulars 4.1 Therapeutic indications Adults: Matrifen is indicated for management of severe chronic pain that requires continuous long term opioid administration. Children: Long term management of severe chronic pain in children from 2 years of age who are receiving opioid therapy. 4.2 Posology and method of administration Posology Matrifen doses should be individualised based upon th Đọc toàn bộ tài liệu